BCL9
Summary: BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| B cell CLL/lymphoma 9 | MIM:602597 | Ensembl:ENSG00000116128 | HGNC:HGNC:1008 | PA25318 | 1q21.2 |
Gene Categories:
TRANSCRIPTION FACTOR COMPLEXGO terms in BCL9
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IEA | GO:0003713 | transcription coactivator activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0008013 | beta-catenin binding |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0005801 | cis-Golgi network |
| CC | IDA | GO:1990907 | beta-catenin-TCF complex |
| CC | IPI | GO:1990907 | beta-catenin-TCF complex |
| BP | IEA | GO:0014908 | myotube differentiation involved in skeletal muscle regeneration |
| BP | IMP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway |
| BP | IEA | GO:0035019 | somatic stem cell population maintenance |
| BP | IEA | GO:0035914 | skeletal muscle cell differentiation |
| BP | IEA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0060070 | canonical Wnt signaling pathway |
| BP | TAS | GO:1904837 | beta-catenin-TCF complex assembly |
Gene expression in normal tissue: BCL9
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in BCL9
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-195721 | Signaling by WNT |
| reactome | R-HSA-201681 | TCF dependent signaling in response to WNT |
| reactome | R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| reactome | R-HSA-3769402 | Deactivation of the beta-catenin transactivating complex |
| pid | betacatenin_nuc_pathway | Regulation of nuclear beta catenin signaling and target gene transcription |
| netpath | Pathway_Wnt | Wnt |
| wikipathways | WP363 | Wnt Signaling Pathway |
| wikipathways | WP3658 | Wnt-beta-catenin Signaling Pathway in Leukemia |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD446 | LY 2183240 | 5 |
| iGMDRD193 | Fqi1 | 2 |
| iGMDRD297 | Austocystin D | 1 |
| iGMDRD466 | Chaetocin | 3 |
| iGMDRD433 | Lexibulin | 3 |
| iGMDRD151 | CHM-1 | 4 |
| iGMDRD779 | PRL-3 Inhibitor I | 3 |
| iGMDRD483 | SCH-529074 | 1 |
| iGMDRD462 | OSI-906 (Linsitinib) | 1 |
| iGMDRD494 | Neopeltolide | 2 |
| iGMDRD188 | Piperlongumine | 5 |
| iGMDRD506 | Fedratinib | 1 |
| iGMDRD577 | BIX01294 | 4 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD60 | Quinoclamine | 2 |
| iGMDRD270 | Ciclosporin | 1 |
| iGMDRD260 | FQI-2 | 4 |
| iGMDRD255 | SB225002 | 3 |
| iGMDRD171 | Pemetrexed | 4 |
| iGMDRD318 | PAC-1 | 2 |
| iGMDRD226 | ML006 | 2 |
| iGMDRD341 | Triacsin c | 3 |
| iGMDRD85 | Ursolic acid | 3 |
| iGMDRD237 | ABT-751 | 4 |
| iGMDRD123 | Isoevodiamine | 3 |
| iGMDRD511 | CHEMBL399379 | 2 |
| iGMDRD330 | BRD4132 | 2 |
| iGMDRD512 | nutlin 3 | 6 |
| iGMDRD345 | Compound 10b [PMID: 11504634] | 2 |
| iGMDRD299 | ICL 670 | 1 |
| iGMDRD286 | Nsc 632839 | 5 |
| iGMDRD414 | MST-312 | 2 |
| iGMDRD329 | Merck60 | 3 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD103 | SN-38 | 1 |
| iGMDRD137 | Indisulam | 2 |
| iGMDRD105 | Triptolide | 2 |
| iGMDRD705 | Nakiterpiosin | 3 |
| iGMDRD434 | BMS-536924 | 2 |
| iGMDRD77 | Itraconazole | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in BCL9
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.